<p>Early- and late-onset preeclampsia (EOPE and LOPE) pose serious maternal-fetal risks, yet non-invasive early prediction remains challenging. In a prospective cohort of 9,586 pregnancies, we analyze trimester-specific plasma cell-free RNA (cfRNA) profiles from 42 EOPE and 43 LOPE cases versus 131 normotensive controls. Organ-specific transcriptomic shifts distinguish EOPE from LOPE. Predictive models based on cfRNA signatures identify EOPE up to 18.0 weeks before clinical onset in the first-trimester (T1) (AUC = 0.88), and 8.5 weeks in the second trimester (T2) (AUC = 0.89). LOPE is predicted 14.9 weeks in advance using T2 data (AUC = 0.90), while T1 performance is lower (AUC = 0.68). External validation confirms robust EOPE prediction (AUC = 0.87 at T1; 0.81 at T2) and acceptable LOPE performance (AUC = 0.63 at T1; AUC = 0.77 at T2). EOPE models are enriched for decidual transcripts, suggesting early maternal involvement; LOPE models reflect broader tissue contributions. These findings offer a path to early, non-invasive, subtype-specific preeclampsia risk stratification and prevention.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Maternal plasma cell-free RNA as a predictor of early and late-onset preeclampsia throughout pregnancy

  • Nerea Castillo-Marco,
  • Teresa Cordero,
  • Marina Igual,
  • Irene Muñoz-Blat,
  • Carla Gómez-Álvarez,
  • Neus Bernat-González,
  • Ángela Gaspar-Doménech,
  • Érika Ortiz-Domingo,
  • Alba Vives,
  • Sheila Ortega-Sanchís,
  • Rogelio Monfort-Ortiz,
  • Petr Volkov,
  • Juan Luis Delgado,
  • Laura Hernandez-Hernandez,
  • Esther Canovas,
  • Maria del Mar Gil,
  • Belén Santacruz,
  • Nieves Luisa Gonzalez-Gonzalez,
  • Walter Plasencia,
  • Alfredo Perales-Marín,
  • Beatriz Marcos-Puig,
  • Ana María Palacios-Marqués,
  • Íñigo Melchor,
  • Alicia Martin-Martinez,
  • Taysa Benitez-Delgado,
  • A. Aiartzaguena,
  • S. Alonso-Menéndez,
  • A. Amezcua,
  • C. Andrada-Ripolles,
  • EM Arias-Valdés,
  • AM Arnal-Burró,
  • MJ Barbazán,
  • R. Batalla-Urrea,
  • P. Baviera-Royo,
  • M. Bondía,
  • J. Burgos,
  • CR Cabrera-Leon,
  • JM Campillos-Maza,
  • MC Casanova,
  • D. Cuenca-Gómez,
  • C. De Bonrostro-Torralba,
  • S. De Leon-Socorro,
  • A. Del Campo,
  • JL Delgado-Gonzalvez,
  • P. Diaz-Lozano,
  • M. Fabre,
  • E. Ferrer,
  • S. Florez-Perez,
  • J. Francés-Ferré,
  • O. García-Izquierdo,
  • V García-Sousa,
  • E. Gibbone,
  • H. Goiti,
  • A. Gomez,
  • E. Gonzalez,
  • SE Gregorio-González,
  • M. Hernández-Suárez,
  • R. Herrero-Serrano,
  • A. Jimenez-Mendez,
  • MA Jodar-Perez,
  • MM Larrea-Ortíz Quintana,
  • A. Lasierra-Beamonte,
  • RM Lobo-Valentín,
  • A. López-Soto,
  • A. Lozano-Moreno,
  • MJ Macías-Alonso,
  • A. Martin-Arias,
  • EM Martín-Medrano,
  • JP Martínez-Cendán,
  • I. Martinez-Rivero,
  • A. Meabe,
  • JC Melchor,
  • Y. Mico,
  • M. Montesinos-Albert,
  • A. Moreno-Reviriego,
  • M. Nieto-Tous,
  • A. Orive-Boluda,
  • D. Oros,
  • E. Padrón-Pérez,
  • C. Paules,
  • SM Peña-Lobo,
  • E. Pérez-Pascual,
  • V Recio,
  • C. Reula-Blasco,
  • L. Rodríguez,
  • MI Romero,
  • L. Rubert,
  • S. Ruiz-Martinez,
  • AC Ruiz-Peña,
  • A. Salinas,
  • E. Sanchez-Martinez,
  • E. Satorres-Pérez,
  • E. Villar-Graullera,
  • Carlos Simón,
  • Tamara Garrido-Gómez

摘要

Early- and late-onset preeclampsia (EOPE and LOPE) pose serious maternal-fetal risks, yet non-invasive early prediction remains challenging. In a prospective cohort of 9,586 pregnancies, we analyze trimester-specific plasma cell-free RNA (cfRNA) profiles from 42 EOPE and 43 LOPE cases versus 131 normotensive controls. Organ-specific transcriptomic shifts distinguish EOPE from LOPE. Predictive models based on cfRNA signatures identify EOPE up to 18.0 weeks before clinical onset in the first-trimester (T1) (AUC = 0.88), and 8.5 weeks in the second trimester (T2) (AUC = 0.89). LOPE is predicted 14.9 weeks in advance using T2 data (AUC = 0.90), while T1 performance is lower (AUC = 0.68). External validation confirms robust EOPE prediction (AUC = 0.87 at T1; 0.81 at T2) and acceptable LOPE performance (AUC = 0.63 at T1; AUC = 0.77 at T2). EOPE models are enriched for decidual transcripts, suggesting early maternal involvement; LOPE models reflect broader tissue contributions. These findings offer a path to early, non-invasive, subtype-specific preeclampsia risk stratification and prevention.